Venture-Backed Startups

Aegeantic builds AI-powered agents, digital platforms, and enterprise system integrations designed to run on-premise for secure data control. The company serves businesses seeking intelligent automation and scalable digital ecosystems with a focus on data sovereignty and operational transformation.

1 investor

Unicorn is an autonomous solar panel cleaning robot that uses water-free brushing technology to remove dust and soiling from ground-mounted and rooftop installations, operating at scale without manual intervention.

1 investor

0 investors

Aegiq develops networked photonic quantum systems, including a quantum computer and photon sources, intended for practical large-scale deployment. Its offerings span quantum computing hardware, optical fibre security, and software tooling for building and running quantum workflows.

3 investors

Aegis provides a platform to healthcare providers and hospitals that automates insurance denial appeals and resubmissions to recover lost revenue. The system prioritizes denials by financial impact and overturn likelihood, and integrates with major EHRs and insurance providers.

3 investors

aegis is a personal safety app that enables users to alert emergency responders with location, medical information, and context without requiring speech. The platform serves individuals who need quick access to help during emergencies, accidents, or unsafe situations.

1 investor

0 investors

0 investors

0 investors

0 investors

Aegis Response Team provides public safety and emergency response services, including alternative and innovative offerings such as traffic crash response, delivered to cities and police departments through public-private partnerships. The company operates in the U.S. law enforcement and public safety services sector.

0 investors

Aegis operates a clinical laboratory providing definitive drug and substance testing services for healthcare providers, pharmaceutical companies, sports organizations, and corporations. The company offers medication monitoring, drug screening, and laboratory analytics integrated with electronic medical records systems.

2 investors

0 investors

0 investors

AEGIS AI provides autonomous AI-driven red teaming and phishing simulations for enterprise security teams. The platform uses generative agents to conduct open-source intelligence and create personalized social engineering lures to test employee security awareness without capturing actual credentials.

3 investors

Aegis Custody is a blockchain company that holds digital assets in segregated custody accounts, operating under a TCSP license in Hong Kong and a South Dakota Charter in the US. It provides regulated custody and trust/company services for holders of digital assets.

1 investor

AegisNet builds a physical net barrier designed to stop high-energy FPV drone strikes and protect crews and critical payloads in the final meters. Its modular, mountable systems serve military vehicles, shelters, container systems, and personnel in urban environments, positioned as Finnish counter-UAS defense technology.

1 investor

AV (AeroVironment) develops integrated defense systems spanning air, land, sea, and space, including unmanned aircraft, counter-UAS, loitering munitions, directed energy, and autonomy software for allied military operators. Its MacCready Works group builds mission-ready autonomous robotic systems, with deployments reported across more than 55 countries.

1 investor

Aegle Capital, a trade name of Aegle Health Partners, Inc., provides financing for commercial healthcare businesses. The firm focuses on healthcare-sector capital.

2 investors

A seed and early-stage investment fund based in Chattanooga that backs companies with demonstrated traction and growth potential across the southeastern United States. The fund provides capital alongside mentorship and strategic guidance to entrepreneurs beyond the concept stage.

1 investor

3 investors

Aegle Therapeutics develops therapies using extracellular vesicles (EVs) isolated from mesenchymal stem cells to deliver therapeutic biomolecules to diseased and damaged cells. Its lead product, AGLE-102, targets dystrophic epidermolysis bullosa, a rare pediatric skin-blistering disease, with potential applications across dermatology, immunology, and protein-deficiency disorders.

4 investors

0 investors

Spyre Therapeutics develops monoclonal antibodies with extended half-lives targeting inflammatory bowel disease and rheumatic conditions including rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The company is advancing single-agent and combination antibody therapies designed to enable less frequent subcutaneous dosing while addressing unmet treatment needs in these immune-mediated diseases.

2 investors